Llwytho...
Targeting wild-type KRAS amplified gastroesophageal cancer through combined MEK and SHP2
The role of KRAS, when activated through canonical mutations, has been well established in cancer(1). Here we explore a secondary means of KRAS activation in cancer, focal high-level amplification of the KRAS gene in the absence of coding mutations. These amplifications occur most commonly in esopha...
Wedi'i Gadw mewn:
Cyhoeddwyd yn: | Nat Med |
---|---|
Prif Awduron: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Fformat: | Artigo |
Iaith: | Inglês |
Cyhoeddwyd: |
2018
|
Pynciau: | |
Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6039276/ https://ncbi.nlm.nih.gov/pubmed/29808010 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41591-018-0022-x |
Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|